[{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Telavancin Hydrochloride","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Telavancin Hydrochloride","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Telavancin Hydrochloride","moa":"Cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ SciClone Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Telavancin Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Vibativ (telavancin) is a lipoglycopeptide antibacterial indicated for the treatment of adult patients with complicated skin & skin structure infections caused by susceptible Gram-positive bacteria.

                          Product Name : Vibativ

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          February 18, 2025

                          Lead Product(s) : Telavancin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : SciClone Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Vibativ® (telavancin) Injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA.

                          Product Name : Vibativ

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 31, 2022

                          Lead Product(s) : Telavancin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Tabuk Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including HABP and VABP that can result from COVID-19, flu and other infections.

                          Product Name : Vibativ

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          June 21, 2021

                          Lead Product(s) : Telavancin Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank